on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.
NEWS: New drug begins testing as first-line treatment for fatal childhood disease
International clinical trial for NI-0501 in hemophagocytic lymphohistiocytosis implements protocol amendment across multiple investigational sites in the US and Europe. (16 MAR 2014)
NEWS: Tiziana Life Sciences licenses foralumab from Novimmune
Tiziana Life Sciences plc and Novimmune announced an exclusive license agreement for the clinical development and commercialization of foralumab, a fully human anti-CD3 monocloncal antibody also known as NI-0401. (22 DEC 2014)